Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Biocryst Pharma Inc (BCRX)

9.24   0.175 (1.93%) 01-21 00:45
Open: 9.04 Pre. Close: 9.065
High: 9.4 Low: 8.84
Volume: 4,894,063 Market Cap: 1,631M
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase III clinical trials to treat hereditary angioedema; BCX9930, an oral factor D inhibitor, which is in Phase I clinical trials for mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors that is in Phase I clinical trials to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trials to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 9.406 - 9.433 9.433 - 9.465
Low: 8.758 - 8.791 8.791 - 8.828
Close: 9.18 - 9.231 9.231 - 9.289

Technical analysis

as of: 2021-01-20 4:44:49 PM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 10.98     One year: 12.82
Support: Support1: 7.81    Support2: 6.83
Resistance: Resistance1: 9.40    Resistance2: 10.98
Pivot: 7.94
Moving Average: MA(5): 8.77     MA(20): 7.85
MA(100): 5.18     MA(250): 4.31
MACD: MACD(12,26): 0.59     Signal(9): 0.50
Stochastic oscillator: %K(14,3): 91.10     %D(3): 90.83
RSI: RSI(14): 75.19
52-week: High: 9.40  Low: 1.58  Change(%): 208.0
Average Vol(K): 3-Month: 684040  10-Days: 484989

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.
BCRX has closed below upper band by 0.7%. Bollinger Bands are 71.4% wider than normal. The large width of the bands suggest high volatility as compared to BCRX's normal range. The bands have been in this wide range for 1 bars. This is a sign that the current trend might continue.

Headline News

Wed, 20 Jan 2021
BioCryst Pharmaceuticals Inc. (BCRX) Soars 1.93% on January 20 -

Tue, 19 Jan 2021
BioCryst Pharmaceuticals Inc. (BCRX) Breaks into New 52-Week High on January 19 Session -

Tue, 19 Jan 2021
BioCryst Pharmaceuticals Inc. (BCRX) Soars 3.01% on January 19 -

Mon, 18 Jan 2021
BioCryst Pharmaceuticals Inc. (BCRX) Soars 2.44% on January 18 -

Fri, 15 Jan 2021
BioCryst Pharmaceuticals Inc. (BCRX) Soars 2.44% on January 15 -

Fri, 15 Jan 2021
First Week of September 17th Options Trading For BioCryst Pharmaceuticals (BCRX) - Nasdaq

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 177
Shares Float (M) 162
% Held by Insiders 0.85
% Held by Institutions 73.95
Shares Short (K) 37,040
Shares Short P. Month (K) 38,070

Stock Financials

EPS -0.800
EPS Est This Year -0.750
EPS Est Next Year -0.780
Book Value (p.s.) 0.190
Profit Margin -233.45
Operating Margin -228.81
Return on Assets (ttm) -57.4
Return on Equity (ttm)
Qtrly Rev. Growth 243.8
Gross Profit (p.s.) -0.353
Sales Per Share 0.303
EBITDA (p.s.) -0.689
Qtrly Earnings Growth
Operating Cash Flow (M) -103
Levered Free Cash Flow (M) -64

Stock Valuations

PE Ratio -11.55
PEG Ratio
Price to Book value 48.63
Price to Sales 30.48
Price to Cash Flow -15.84

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.